



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/616,884	07/10/2003	Brian M. Hatcher	5853-428	2636

7590 11/16/2007
AKERMAN SENTERFITT
222 Lakeview Avenue, Suite 400
P. O. Box 3188
West Palm Beach, FL 33402-3188

EXAMINER

YOUNG, MICAH PAUL

ART UNIT	PAPER NUMBER
----------	--------------

1618

MAIL DATE	DELIVERY MODE
-----------	---------------

11/16/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/616,884

Applicant(s)

HATCHER ET AL.

Examiner

Micah-Paul Young

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 August 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 11-44 is/are pending in the application.
- 4a) Of the above claim(s) 39-44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 11-38 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Election/Restrictions

1. Newly submitted claims 39-44 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the new claims are drawn to the previously restricted sol-gel composite material. The restricted material is gelled and comprises different components than the elected composite invention.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 39-44 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 11,13-17,21,23,24,26-30,32,34,36 and 37 are rejected under 35 U.S.C. 102(b) as being anticipated by Boyce et al (USPN 6,294,041 hereafter '041). The claims are drawn to a composite material comprising a calcium and phosphate molecule along with various active and inactive ingredients. The claims are also drawn to a method of repairing tissues using the composite material, as well as a method making the composite by mixing the ingredients together.

Art Unit: 1618

3. The '041 patent teaches an osteoimplant comprising calcium phosphate, active agents and other common ingredients (abstract). The implant comprises bioabsorbable polymers and excipients such as starches, polymethyl methacrylates, polyethylene and other common polymers (col. 4, lin. 25-40). The implant further comprises bioactive compounds such as antiviral agents, and biological compounds such as stem cells and collagen, along with various growth factors (col. 4, lin. 60-col. 5, lin. 15). The implant is applied to an injured or defective area in order to repair the effected area (col. 5, lin. 65-col. 6, lin. 25). The collagen is surface bonded to the implant (col. 6, lin. 26-35). The composition is present in various forms including fibers (example 1). Theses disclosures render the claims anticipated.

4. Claims 11-14,26,27,28,30,31, and 34-36 are rejected under 35 U.S.C. 102(b) as being anticipated by Lee et al (USPN 6,027,742 hereafter '742). The claims are drawn to a composite material comprising a calcium and phosphate molecule along with various active and inactive ingredients. The claims are also drawn to a method of repairing tissues using the composite material, as well as a method making the composite by mixing the ingredients together.

5. The '742 patent teaches a bioresorbable ceramic composite comprising calcium phosphate and other materials (abstract). The composite comprises collagen, demineralized bone and other natural material 1 (col. 9, lin. 45-48) as well as polymers such as polyesters of carboxylic acids (col. 9, lin. 50-55). The further includes harvested cells that are seeded into the implant and proliferate at the implantation site (col. 12, lin. 10-22). The composites are formed by well-known methods including mixing, blending and alloying (col. 13, lin. 62-65). The

Art Unit: 1618

particles produced range in size from 25-200 microns (example 6). These disclosures render the claims anticipated.

6. Claims 11,12,17-19,30,33,36 and 37 are rejected under 35 U.S.C. 102(b) as being anticipated by Marotta et al (USPN 5,990,380 hereafter '380). The claims are drawn to a composite material comprising a calcium and phosphate molecule along with various active and inactive ingredients. The composite comprises fibers that are equally spaced. The claims are also drawn to a method of repairing tissues using the composite material, as well as a method making the composite by mixing the ingredients together.

7. The '380 patent teaches a bioglass implant comprising calcium and phosphate molecules in a composite with others compounds (abstract, table 1). The particles are below 100 microns (col. 6, lin. 5-12) and are present in fibers that are spaced from 20-200 microns apart (claims, examples). The composite is formed at room temperature by mixing the components (examples). These disclosures render the claims anticipated.

8. Claims 11-13,21,22, and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Ducheyne et al (USPN 5,676,720 hereafter '720). The claims are drawn to a composite material comprising a bioglass and biologically active agents. The composite is delivered for sustained release profile.

9. The '720 patent teaches a porous bioglass composite comprising calcium and phosphate molecules (abstract) and other compounds (claims). The composite encapsulates an active agent

Art Unit: 1618

such as a cell on its surface and is implanted allowing for sustained interaction with the defective implant area (col. 8, lin. 44-65). These disclosures render the claims anticipated.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

10. Claims 11, 20, and 36-38 are rejected under 35 U.S.C. 102(a, e) as being anticipated by Niederauer et al (USPN 6,344,496 hereafter '496). The claims are drawn to a bioglass composite comprising a calcium and phosphate molecule along with other common excipients. The composite has a porosity of at least 50%. The claims further recite a method of making the composite where the temperature is below 200 degrees Celsius and the composition is sprayed or extruded.

11. The '496 patent teaches a bioglass composite comprises a calcium and phosphate bioglass compound (col. 4, lin. 19-38). The composite further comprises polymers known in the art such as polyglycolide and glycolide/lactide copolymers (col. 5, lin. 62-col. 6, lin. 18). The composite is used as an implantable device (col. 6, lin. 49-59). The porosity of the composite is

Art Unit: 1618

between 60-90 % (col. 8, lin. 5-15). The composite is formed at room temperature and is spray-dried (examples). These disclosures render the claims anticipated.

Response to Arguments

12. Applicant's arguments filed 8/23/07 have been fully considered but they are not persuasive. Applicant argues that:

- a. The Boyce reference does not anticipates the claims since it does not disclose a true glass as instantly claimed.
- b. The Lee reference does not anticipate the claims since it does not disclose a true glass as instantly claimed.
- c. The Marotta reference does not anticipate the claims since it does not disclose the sol-gel process of the instant claims.
- d. The Ducheyne reference does not anticipate the claims since it does not discloses a sol-gel processing steps as instantly claimed.
- e. The Niederauer reference does not anticipate the claims since it does not disclose a continuous sol-gel process of the instant claims.

13. Regarding argument a., it remains the position of the Examiner that the Boyce patent anticipates the claims. Applicant argues that the claims are drawn to a true glass as defined by Merriam-Webster Online Dictionary. Applicant argues that these true glasses are different and distinct form the bio-glasses of the prior art. However Applicant specification at paragraph [0055] states that: "the term "bioglass" refers to those materials, including BIOGLASS". Further according to the definition of the true glass, the material is formed from a melt procedure. The

Art Unit: 1618

composite of the instant claims, according to the specification is not formed from a melt procedure but rather a sol-gel procedure, a separate and distinct procedure. The claims are drawn to a composite material, not a process of making such. As such the claims are defined by their components, namely a biocompatible polymer and a bioactive glass including at least one calcium and one phosphorous molecular species. The implants of the Boyce patent are demineralized bone materials that have tri-calcium phosphate added as a filler material along with biocompatible polymers such as bioglass, starches, polyglycolide polylactides and polymethyl methacrylate (col. 4, lin. 25-35). Though the implant is bone derived and demineralized (minerals such as calcium removed via an acid process), the added fillers that include bioglass and tri-calcium phosphate and other biocompatible polymers meet the limitations of the claims.

Applicant argues that the invention lacks crystallinity however this is not reflective in the instant claims. The claims are drawn to a bioglass composite comprising a bio glass and a biocompatible polymer. The Boyce patent meets the limits of the claims and therefore anticipates the claims.

14. Regarding argument b., it is the position of the Examiner that the Lee patent anticipates the claims. Applicant continues to argue that the claims recite a true glass composite, however according to the specification bioglass materials meet the limitations of the invention. The claims require a biocompatible polymer, a bioglass material, a calcium and phosphorous molecule. The patent discloses a bioresorbable polymer implant with low crystallinity, calcium phosphate and a supplementary material (abstract). The supplemental materials include biocompatible polymers such as bio active glass compositions include calcium, silicon and phosphorous oxide (col. 9, lin. 55-63) and polyglycolide polymers (col. 9, lin. 40-55). These disclosures meet the limitations of

Art Unit: 1618

the claims. The Lee patent discloses harvested cells, particles and a method of making including mixing, blending all meeting the limitations of the claims (col. 12, lin. 10-22; col. 13, lin. 62-65 and example 6). Each of these disclosures renders the claims anticipated.

15. Regarding argument c., it remains the position of the Examiner that the disclosures of the Marotta patent anticipate the claims. Applicant argues that the prior art does not disclose the sol-gel continuous process of the instant invention. However the claims do not recite a continuous sol-gel process. The claims recite a mixing process for making the composite comprising mixing and hydrolyzing the mixture. The Marotta patent discloses this process along with a disclosure of the spacing of the imbedded fibers (claims). These disclosures render the claims anticipated.

16. Regarding argument d., it is the position of the Examiner that the patent continues to anticipate the claims. Applicant argues that the invention of the Ducheyne patent does not disclose a composite as described in the instant claims. During processing the bioactive glass components are mixed with binders such as polyvinyl alcohol, a biocompatible polymer (col. 6, lin. 15-24). These disclosures meet the limitations of the claims.

17. Regarding argument e., it is the position of the Examiner that the Niederauer patent anticipates the claims. The patent discloses a bioactive glass composite comprising bioactive glass components combined with biocompatible polymers (abstract, col. 4, lin. 19-27; col. 5, lin. 63-67). Again applicant argues the crystallinity of the composition in that the patent is drawn to a ceramic while the invention is a true glass. These crystalline features are not represented in the claims. As discussed above, the specification recites that BIOGLASS materials meet the limitations of the invention. Irrespective of crystallinity these compounds meet the limitations of the bioactive glass limitations. The process of the instant claims requires mixing and

Art Unit: 1618

hydrolyzing. There is no gelling involved. The Niederauer patent anticipates the process of the instant claims (examples).

18. For these reasons at least the discussed patent continue to anticipate the instant claims.

Conclusion

19. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608. The examiner can normally be reached on M-F 6:00-3:30 every other Monday off.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


MP Young

Micah-Paul Young
Examiner
Art Unit 1618


MICHAEL G. HARTLEY
SUPERVISORY PATENT EXAMINER